CN115970059A - Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof - Google Patents
Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof Download PDFInfo
- Publication number
- CN115970059A CN115970059A CN202210867082.4A CN202210867082A CN115970059A CN 115970059 A CN115970059 A CN 115970059A CN 202210867082 A CN202210867082 A CN 202210867082A CN 115970059 A CN115970059 A CN 115970059A
- Authority
- CN
- China
- Prior art keywords
- seq
- elastin
- polypeptide
- skin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 84
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000002500 effect on skin Effects 0.000 title claims abstract description 19
- 239000011159 matrix material Substances 0.000 title claims abstract description 17
- 239000000945 filler Substances 0.000 claims abstract description 4
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 108010007093 dispase Proteins 0.000 claims description 3
- 238000010894 electron beam technology Methods 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000016942 Elastin Human genes 0.000 abstract description 29
- 108010014258 Elastin Proteins 0.000 abstract description 29
- 229920002549 elastin Polymers 0.000 abstract description 28
- 238000011049 filling Methods 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000033115 angiogenesis Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 108091036078 conserved sequence Proteins 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 101000851054 Homo sapiens Elastin Proteins 0.000 abstract 1
- 102000054289 human ELN Human genes 0.000 abstract 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 238000002513 implantation Methods 0.000 description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 231100000085 chronic toxic effect Toxicity 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- UKPGFKQVRITNFM-KBPBESRZSA-N 2-[[2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetic acid Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)NCC(O)=O)C1=CC=C(O)C=C1 UKPGFKQVRITNFM-KBPBESRZSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010084136 glycyl-arginyl-alanyl-aspartyl-seryl-proline Proteins 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 102000046663 human ADM Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108010037335 tyrosyl-prolyl-glycyl-glycine Proteins 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the technical field of biology, and particularly relates to a composition containing elastin-like polypeptides and an acellular dermal matrix and application thereof. The compositions provided herein include elastin conserved sequences and multiple polypeptides that improve stability; the provided polypeptide is basically homologous or similar to a part of mammalian pig and human elastin and has good biological safety. Has remarkable capacity of promoting the production of skin elastin and angiogenesis; can improve the skin filling effect and has obvious synergistic effect; the provided polypeptide sequence is shorter and more stable; the whole polypeptide production process is short in time consumption, low in cost and easy to operate, is easy to realize large-scale production when being used as a three-dimensional soft tissue filler, has important commercial value in the aspects of medical and American product research and development, and has wide clinical application prospect.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a composition containing elastin-like polypeptides and an acellular dermal matrix and application thereof.
Background
Porcine Acellular Dermal Matrix (PADM) is a dermal biomaterial that removes all cellular components. As a porcine-derived biological mesh, it is very common in clinical wound healing treatment. Since PADM plays a very similar role in promoting fibroblast, collagen and angiogenesis as human Acellular Dermal Matrix (ADM), it is often used to replace human ADM for clinical applications. PADM induces M2 macrophage polarization by stimulating collagen synthesis, stem cell proliferation and differentiation, and expression of associated growth factors, and releases a series of wound healing factors including Matrix Metalloproteinases (MMPs) and growth factors, promoting cell proliferation and angiogenesis, while remodeling the extracellular matrix (ECM).
Elastin is the main component of elastic fibres in animal tissues. Elastin is present in most connective tissues along with collagen and polysaccharides. In normal mammalian skin, especially human skin, the proportion of elastin proteins in the total skin protein is not very high, but plays a very important role in maintaining the tone, structure and elasticity of the skin. Elastin fibers are capable of stretching to several times their length and then rapidly return to their original dimensions after the tension is released. Thus, elastin contributes to the physiological elasticity of tissue. However, elastin does not penetrate skin sufficiently to provide substantial benefits, since its tightly cross-linked structure makes it difficult to dissolve. With the improvement of living standard, the most demand for beauty becomes a problem to be solved urgently. At present, no report about the application of elastin in acellular dermal matrix is found.
Disclosure of Invention
In view of the above, the present invention provides a composition comprising an elastin-like polypeptide and an acellular dermal matrix, and uses thereof. So that the composition has a synergistic effect, and the activity of promoting the generation of elastin and regenerating blood vessels is obviously increased; and has no acute or chronic toxic effect, and has wide clinical application value and prospect.
In order to achieve the above purpose, the invention provides the following technical scheme:
in one aspect, the invention provides a composition comprising an elastin-like polypeptide and an acellular dermal matrix, the composition comprising an elastin-like polypeptide and an acellular dermal matrix; the polypeptide comprises one or more of the amino acid sequences shown in Seq _ 1-12.
Preferably, the elastin-like polypeptide includes one or more of the amino acid sequences set forth in Seq _1, 3, 4, 5, 9, or/and 10.
The composition further comprises any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.
In another aspect, the present invention also provides a method for preparing an acellular dermal matrix, comprising the steps of:
(1) Cleaning, cutting off subdermal adipose tissue and removing hair;
(2) Removing epidermis of skin with 0.25% trypsin solution, chopping dermis, further placing into 0.25% trypsin solution for treatment reaction, and cleaning with 0.1% sodium dodecyl sulfate solution;
(3) Treating the cleaned skin with Dispase solution, washing with 0.1% sodium dodecyl sulfate solution, washing with phosphate buffer solution, pulverizing, and sterilizing with electron beam.
In another aspect, the present invention also provides the use of a composition as described above for the preparation of a micro-profiled material.
Preferably, the material is a soft tissue filler.
The invention also provides an elastin-like polypeptide comprising an amino acid sequence as set forth in Seq _1, seq _2, seq _3, seq _4, seq _5, seq _6, seq _7, seq _8, seq _9, seq _10, seq _11 or Seq _ 12.
Preferably, the polypeptide comprises an amino acid sequence as set forth in Seq _1, seq _3, seq _4, seq _5, seq _9 or Seq _ 10.
The invention also provides a pharmaceutical composition comprising an elastin-like polypeptide comprising one or more of the amino acid sequences set forth in Seq _1, seq _3, seq _4, seq _5, seq _9, or Seq _ 10.
Preferably, the pharmaceutical composition further comprises any one or a combination of at least two of pharmaceutically acceptable carriers, excipients or diluents.
Compared with the prior art, the invention has the beneficial effects that:
(1) The compositions of the invention include elastin conserved sequences and multiple polypeptides that improve stability; the polypeptide of the invention is basically homologous or similar to a part of elastin of mammal pigs and human, and has good biological safety.
(2) The polypeptide provided by the invention has remarkable capacity of promoting the production of skin elastin and angiogenesis; the provided PADM and polypeptide composition has the capability of remarkably improving the skin filling effect and has an obvious synergistic effect;
(3) The polypeptide provided by the invention has shorter and more stable sequence; the whole polypeptide production process is short in time consumption, low in cost and easy to operate, is easy to realize large-scale production when being used as a three-dimensional soft tissue filler, has important commercial value in the aspects of medical and American product research and development, and has wide clinical application prospect.
Drawings
FIG. 1 is a graph of the ability of a polypeptide to produce elastin;
FIG. 2 is a graph of the ability of different concentrations of polypeptide compositions to produce elastin;
FIG. 3 is a graph of filling results 10 days after implantation of different materials;
FIG. 4 is a graph of filling results 30 days after implantation of different materials;
fig. 5 is a graph of HE staining of implants of the PADM + polypeptidyl.
Detailed Description
The invention discloses a composition containing elastin-like polypeptide and acellular dermal matrix and application thereof. It is specifically noted that all such substitutions and modifications will be apparent to those skilled in the art and are intended to be included herein. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations and modifications, or appropriate variations and combinations of the methods and applications described herein may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention. The methods, devices and materials used in the examples which follow, if not specifically indicated, are all conventional and commercially available methods, devices and materials used in the art.
Example 1: preparation of porcine acellular dermal matrix
Obtaining fresh pig skin from local slaughterhouse, thoroughly cleaning, cutting subcutaneous adipose tissue and removing hair, and cutting the obtained skin into 5 × 5 × 0.3 cm 3 The small blocks are stored in a refrigerator at the temperature of 20 ℃ below zero for standby. The treated pigskin was treated with a 0.25% trypsin (Biosharp) solution at 25 ℃ for 18 hours to remove the skin epidermis, and then the dermal section was cut into sections of 0.5X 0.3 cm 3 The fragments of (a); shaking with 0.25% trypsin solution at 25 ℃ for 12 hours on a shaker; the pigskin was washed with 0.1% sodium dodecyl sulfate (SDS, chinese medicine) solution for 12 hours at room temperature, followed by 560U/L Dispase (Roche) solution for 12 hours at 25 ℃. Next, the pigskin was washed with 0.1% SDS at room temperature for 12 hours and then twice with Phosphate Buffered Saline (PBS) (15 minutes each). And further crushing the treated pigskin by using a crusher, and sending the pigskin to a tin-free Futeng irradiation company for electron beam sterilization to obtain the pig acellular dermal matrix. It was freeze-dried and stored in a-80 ℃ refrigerator.
Example 2: screening for active Polypeptides
BLAST homology analysis is carried out on human and pig elastin sequences, sequences with higher conservation degree among species are taken, and elastin polypeptides are designed according to the principle of higher polypeptide stability. The peptide sequence was synthesized by Kinseri. The synthetic polypeptides are recorded as polypeptides 1 to 12; the amino acid sequence is shown in Seq _ 1-12. Namely respectively corresponding to:
polypeptide 1: D-Gly D-Ala D-Val D-Val D-Pro D-Gln;
polypeptide 2D-Phe D-Pro D-Gly Ala Leu Val Pro D-Gly D-Gly D-Val
Polypeptide 3D-Pro D-Gly D-Val D-Gly D-Pro
Polypeptide 4: D-Thr D-Gly D-Lys Leu D-Pro D-Tyr D-Gly
Polypeptide 6, D-Lys D-Pro D-Gly Lys Val Pro Gly D-Val D-Gly D-Leu
Polypeptide 7, D-Pro D-Gly D-Val Tyr Pro Gly Gly Val D-Leu D-Pro D-Gly
Polypeptide 8, D-Gln D-Pro D-Gly Val Pro Leu Gly D-Tyr D-Pro D-Ile
Polypeptide 9, D-Leu D-Pro D-Gly Val D-Pro D-Thr D-Gly
Polypeptide 10, D-Gly D-Gly D-Ala Phe D-Ala D-Gly D-Ile
Polypeptide 11, D-Lys D-Ala D-Pro Lys Leu Pro Gly Gly Tyr Gly D-Leu D-Pro D-Tyr
The polypeptide 12 is D-Aal D-Gly D-Tyr Pro Thr Gly Thr D-Gly D-Val D-Gly.
The elastin polypeptide solution was prepared with physiological saline, and 1.5% elastin polypeptide solution was injected subcutaneously (wt/wt) into SD rats (3 per group), respectively, and the amino acid sequence of the negative control polypeptide was shown as Seq _ 13 (GRADSP). Three skin samples were taken from the treatment sites of each animal and the results averaged for each animal. FIG. 1 is a graph of the ability of polypeptides to produce elastin; as can be seen in fig. 1, there was a significant increase in elastin levels (measured as the ratio of elastin micrograms (μ g) to dry weight per milligram (mg) of fat-free skin) in rats using polypeptides 1, 3, 4, 5, 9 and 10 after 30 days compared to the negative control polypeptide. Therefore, the screened polypeptides 1, 3, 4, 5, 9 and 10 can promote the production of skin elastin. Elastin quantification was accurately quantified using the method of Sandberg, et al, (connecting Tissue research. 25: 139-48, 1990).
Example 3: effect of polypeptide compositions on elastin expression
Example 4: polypeptide composition and filling effect after pig acellular dermal matrix implantation
Depilating the back of a male Balb/c mouse aged 6 weeks, confirming that the depilating is clean and has no inflammation, and randomly dividing the depilating into a PADM group, a polypeptide group and a PADM + polypeptide group; 6 mice per group; the PADM group is only injected with PADM, the polypeptide group is only injected with the polypeptide composition with a medium dosage, and the PADM + polypeptide group is simultaneously injected with the polypeptide composition with a medium dosage; the dosage of the polypeptide is 200 mug/Kg, and the dosage of the PADM is 10 g/Kg (calculated by wet weight). Injecting 0.5ml of corresponding product into each mouse subcutaneously, observing whether outflow exists after injection, and enabling the mice successfully injected to enter cages for observation. The status of the mice was observed daily. Table 1 is a comparative table of toxicity observations in vivo for each group of mice.
TABLE 1 Observation of the toxic Effect of the Polypeptides and PADM in mice
As shown in Table 1, after the polypeptide and PADM provided by the invention are injected into mice, no obvious influence is caused on factors such as normal diet, excretion and exercise of the mice, all recorded ethological indications are normal, and no death phenomenon of the mice is found one day, one week and 30 days after the injection. Proved that after the polypeptide and the PADM are implanted into mice, the polypeptide and the PADM have no obvious acute or chronic toxic effect on the mice.
The size of the implants in each group was measured at 10 and 30 days each, and sacrificed and dissected after 30 days of measurement. It was observed that 10 days after implantation, the development size of the PADM + polypeptide group and PADM group did not differ much, and there was no inflammation in all three groups. After 30 days of implantation, the PADM + polypeptide group and PADM group implants were hemispherical, and the implant volume of PADM + polypeptide group was significantly different from that of other two groups, and the volume was significantly increased. FIG. 3 is a graph of fill results 10 days after implantation of different materials; FIG. 4 is a graph of the filling results 30 days after implantation of different materials; as shown in fig. 3 and 4, compared with the PADM combination polypeptide group, the PADM and polypeptide group have significantly larger volume than the PADM group, so that the skin filling effect is significantly improved, and the PADM and polypeptide combination has a synergistic effect.
The implants of the PADM + polypeptidyl were HE stained and photographs taken. FIG. 5 is a graph of HE staining of implants from the PADM + polypeptide set (scale bar 100 μm); as can be seen from fig. 5, the implant can be roughly divided into 3 layers from the surface to the inside, and is loose, compact and uniform; the surface of the implant has a multilayer tissue structure and is provided with abundant blood vessels; the inside has dense cells and capillary vessels. It can be seen that PADM and polypeptides are suitable for cellular invasion and growth.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes performed by the present specification and drawings, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. A composition comprising an elastin-like polypeptide and an acellular dermal matrix; the elastin-like polypeptide includes one or more of the amino acid sequences shown as Seq _ 1-12.
2. The composition of claim 1, wherein the elastin-like polypeptide comprises one or more of the amino acid sequences set forth in Seq _1, 3, 4, 5, 9, or/and 10.
3. The composition of claim 1, further comprising any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient, or diluent.
4. A method for preparing an acellular dermal matrix, comprising the steps of:
(1) Cleaning, cutting off subdermal adipose tissue and removing hair;
(2) Removing epidermis of skin with 0.25% trypsin solution, chopping dermis, further placing into 0.25% trypsin solution for treatment reaction, and cleaning with 0.1% sodium dodecyl sulfate solution;
(3) Treating the cleaned skin with Dispase solution, washing with 0.1% sodium dodecyl sulfate solution, washing with phosphate buffer solution, pulverizing, and sterilizing with electron beam.
5. Use of a composition according to claim 1 for the preparation of a micro-sculpturing material.
6. Use according to claim 5, wherein the material is a soft tissue filler.
7. An elastin-like polypeptide, comprising an amino acid sequence as set forth in Seq _1, seq _2, seq _3, seq _4, seq _5, seq _6, seq _7, seq _8, seq _9, seq _10, seq _11, or Seq _ 12.
8. An elastin-like polypeptide comprising an amino acid sequence as set forth in Seq _1, seq _3, seq _4, seq _5, seq _9 or Seq _ 10.
9. A pharmaceutical composition comprising the polypeptide of claim 8.
10. The pharmaceutical composition of claim 9, further comprising any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient, or diluent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210867082.4A CN115970059A (en) | 2022-07-21 | 2022-07-21 | Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210867082.4A CN115970059A (en) | 2022-07-21 | 2022-07-21 | Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115970059A true CN115970059A (en) | 2023-04-18 |
Family
ID=85965272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210867082.4A Pending CN115970059A (en) | 2022-07-21 | 2022-07-21 | Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115970059A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493261A (en) * | 2003-09-02 | 2004-05-05 | 中国人民解放军第四军医大学口腔医学 | Tissue engineering corium and its preparation method |
| US20050059599A1 (en) * | 1998-03-13 | 2005-03-17 | Connective Tissue Imagineering Llc. | Elastin peptide analogs and uses thereof |
| CN103990179A (en) * | 2014-05-24 | 2014-08-20 | 河北爱能生物科技有限公司 | Method for preparing xenogeneic acellular matrix and product thereof |
-
2022
- 2022-07-21 CN CN202210867082.4A patent/CN115970059A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059599A1 (en) * | 1998-03-13 | 2005-03-17 | Connective Tissue Imagineering Llc. | Elastin peptide analogs and uses thereof |
| CN1493261A (en) * | 2003-09-02 | 2004-05-05 | 中国人民解放军第四军医大学口腔医学 | Tissue engineering corium and its preparation method |
| CN103990179A (en) * | 2014-05-24 | 2014-08-20 | 河北爱能生物科技有限公司 | Method for preparing xenogeneic acellular matrix and product thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2182971B1 (en) | Compositions comprising human collagen and human elastin and uses thereof | |
| CN107849596B (en) | High-purity collagen particles and preparation method and use thereof | |
| KR100612535B1 (en) | Peptide Compositions and Agents and Their Uses | |
| EP2432495B1 (en) | Elastin for soft tissue augmentation | |
| De Vries et al. | Dermal regeneration in native non‐cross‐linked collagen sponges with different extracellular matrix molecules | |
| US20070207180A1 (en) | Synthetic polypeptide-containing bioapplicable material and film-forming material | |
| CN103732614A (en) | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use | |
| Tiwari et al. | AN UPDATED REVIEW ON RECENT DEVELOPMENTS AND APPLI-CATIONS OF FISH COLLAGEN | |
| CN108114320A (en) | Tissue repair sticking patch, main body and preparation method | |
| DE60007973T2 (en) | MATRIX PROTEIN COMPOSITIONS FOR Grafting In Non-Mineralized Tissues | |
| KR20130052441A (en) | Composition and kit comprising recombinant human bone morphogenetic protein and twist transcription factor for skin repair as active ingredient | |
| CN115970059A (en) | Compositions comprising elastin-like polypeptides and acellular dermal matrix and uses thereof | |
| KR20130109849A (en) | Composition and kit comprising recombinant human bone morphogenetic protein for gingival regeneration as active ingredient | |
| RU2353397C2 (en) | Bioabsorbable collagen matrix, method of production and application | |
| CN114716515A (en) | Polypeptide analogue and preparation method and application thereof | |
| CN115970052A (en) | Composition containing laminin-like polypeptide and acellular dermal matrix and application thereof | |
| KR101588309B1 (en) | Peptides, compositions, and uses thereof | |
| TWI791290B (en) | Use of collagen particles in hair follicles formation or angiogenesis | |
| CN115845131A (en) | Compositions comprising fibronectin-like polypeptides and acellular dermal matrix and uses thereof | |
| CN1737129B (en) | Artificial skin graft and preparation method thereof | |
| CN112675294B (en) | Preparation of fibroblast and application of fibroblast in plastic surgery repair | |
| CN110935003A (en) | Biological polypeptide composition for promoting skin injury repair | |
| DE CASTRO et al. | EFFICACY OF COLLAGEN-ONLY SCAFFOLDS COMPARED TO POLYMER-ASSOCIATED COLLAGEN AND NANOMATERIALS IN SKIN WOUND REPAIR-A REVIEW. | |
| CN116983459B (en) | Preparation method of low-immunogenicity absorbable suture based on tendon of castoreum | |
| WO2023039833A1 (en) | Use of collagen particles to promote hair follicle formation or angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |